These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 22486070)

  • 61. Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: a Danish register-based study.
    Dalsgaard S; Nielsen HS; Simonsen M
    J Child Adolesc Psychopharmacol; 2013 Sep; 23(7):432-9. PubMed ID: 24015896
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prefrontal grey and white matter neurometabolite changes after atomoxetine and methylphenidate in children with attention deficit/hyperactivity disorder: a (1)H magnetic resonance spectroscopy study.
    Husarova V; Bittsansky M; Ondrejka I; Dobrota D
    Psychiatry Res; 2014 Apr; 222(1-2):75-83. PubMed ID: 24679996
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Age-specific prevalence, incidence of new diagnoses, and drug treatment of attention-deficit/hyperactivity disorder in Germany.
    Lindemann C; Langner I; Kraut AA; Banaschewski T; Schad-Hansjosten T; Petermann U; Petermann F; Schreyer-Mehlhop I; Garbe E; Mikolajczyk RT
    J Child Adolesc Psychopharmacol; 2012 Aug; 22(4):307-14. PubMed ID: 22856384
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Findings from the observational COMPLY study in children and adolescents with ADHD: core symptoms, ADHD-related difficulties, and patients' emotional expression during psychostimulant or nonstimulant ADHD treatment.
    Dittmann RW; Banaschewski T; Schacht A; Wehmeier PM
    Atten Defic Hyperact Disord; 2014 Dec; 6(4):291-302. PubMed ID: 24705867
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Methylphenidate vs atomoxetine: personalized medicine in attention- deficit/hyperactivity disorder.
    Heinrich H; Studer P; Moll GH; Kratz O
    JAMA Psychiatry; 2013 May; 70(5):545. PubMed ID: 23636880
    [No Abstract]   [Full Text] [Related]  

  • 66. [My child is so restless].
    Schlamp D
    MMW Fortschr Med; 2007 Mar; 149(10):39-40. PubMed ID: 17408047
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Cardiovascular risk assessment for the use of ADHD drugs in children].
    Berg A; Bråtane E; Odland HH; Brudvik C; Rosland B; Hirth A
    Tidsskr Nor Laegeforen; 2014 Apr; 134(7):710-4. PubMed ID: 24721858
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Current Australian pediatric practice in the assessment and treatment of ADHD.
    Efron D; Davies S; Sciberras E
    Acad Pediatr; 2013; 13(4):328-33. PubMed ID: 23830018
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Management of attention-deficit/hyperactivity disorder.
    Jamdar S; Sathyamoorthy BT
    Br J Hosp Med (Lond); 2007 Jul; 68(7):360-6. PubMed ID: 17663306
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Attention deficit hyperactivity disorders in children and adolescents: diagnostic and therapeutic guidelines].
    Lehmkuhl G
    MMW Fortschr Med; 2007 May; 149 Suppl 2():10-3; quiz 14. PubMed ID: 17724960
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Close up on atomoxetine: a nonstimulant choice for treating ADHD.
    Allen C; Pitcock J
    Adv Nurse Pract; 2006 Mar; 14(3):39-40, 42-3, 78. PubMed ID: 16548127
    [No Abstract]   [Full Text] [Related]  

  • 72. Emotional dysregulation in adult ADHD: What is the empirical evidence?
    Retz W; Stieglitz RD; Corbisiero S; Retz-Junginger P; Rösler M
    Expert Rev Neurother; 2012 Oct; 12(10):1241-51. PubMed ID: 23082740
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Long-Term Pharmacotherapy of Adults With Attention Deficit Hyperactivity Disorder: A Literature Review and Clinical Study.
    Fredriksen M; Peleikis DE
    Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):23-31. PubMed ID: 26404187
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Reconsider the diagnosis and treatment approach for ADHD].
    Jacobsson L; Hägglöf B
    Lakartidningen; 2015 Feb; 112():. PubMed ID: 25710238
    [No Abstract]   [Full Text] [Related]  

  • 75. Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder.
    Donnelly M; Haby MM; Carter R; Andrews G; Vos T
    Aust N Z J Psychiatry; 2004 Aug; 38(8):592-601. PubMed ID: 15298581
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Pharmacotherapy of attention-deficit/hyperactivity disorder (ADHD) and comorbid disorders].
    Wiesegger G; Kienbacher C; Pellegrini E; Scheidinger H; Vesely C; Bangerl W; Friedrich M
    Neuropsychiatr; 2007; 21(3):187-206. PubMed ID: 17915180
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database.
    McCarthy S; Cranswick N; Potts L; Taylor E; Wong IC
    Drug Saf; 2009; 32(11):1089-96. PubMed ID: 19810780
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmacotherapy of ADHD in adults.
    Wilens TE
    CNS Spectr; 2008 May; 13(5 Suppl 8):11-3. PubMed ID: 18567133
    [No Abstract]   [Full Text] [Related]  

  • 79. What place for lisdexamfetamine in children and adolescents with ADHD?
    Drug Ther Bull; 2013 Oct; 51(10):114-7. PubMed ID: 24113146
    [TBL] [Abstract][Full Text] [Related]  

  • 80. AAP releases guideline on diagnosis, evaluation, and treatment of ADHD.
    Hauk L
    Am Fam Physician; 2013 Jan; 87(1):61-2. PubMed ID: 23317027
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.